Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-05-01
2009-08-11
Hartley, Michael G (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S167000, C514S731000
Reexamination Certificate
active
07572788
ABSTRACT:
The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, and hyperproliferation, and the like.
REFERENCES:
patent: 3261828 (1966-07-01), Uskokovic et al.
patent: 3384635 (1968-05-01), Calabateas et al.
patent: 3415814 (1968-12-01), Calabateas et al.
patent: 4076823 (1978-02-01), Wade et al.
patent: 4088756 (1978-05-01), Voorhees
patent: 4110337 (1978-08-01), Szarvasi
patent: 4495101 (1985-01-01), Klaubert et al.
patent: 4551480 (1985-11-01), Stiefel
patent: 4751223 (1988-06-01), Glamkowski et al.
patent: 4898861 (1990-02-01), Morgan et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5041438 (1991-08-01), Hsu
patent: 5141930 (1992-08-01), Nakao
patent: 5216148 (1993-06-01), Klaus et al.
patent: 5288514 (1994-02-01), Ellman
patent: 5324726 (1994-06-01), Bock et al.
patent: 5444092 (1995-08-01), Collins
patent: 5559230 (1996-09-01), Ogawa
patent: 5591227 (1997-01-01), Dihn et al.
patent: 5597915 (1997-01-01), Chambers et al.
patent: 5599352 (1997-02-01), Dihn et al.
patent: 5697967 (1997-12-01), Dihn et al.
patent: 5776946 (1998-07-01), McGeer et al.
patent: 5861380 (1999-01-01), Gyorkos et al.
patent: 6004942 (1999-12-01), Firestein et al.
patent: 6074859 (2000-06-01), Hirokawa
patent: 6080588 (2000-06-01), Glick
patent: 6100254 (2000-08-01), Budde et al.
patent: 6277844 (2001-08-01), Spector
patent: 6319931 (2001-11-01), Kroemer et al.
patent: 6506744 (2003-01-01), Alig
patent: 6524623 (2003-02-01), Hodosh
patent: 6524832 (2003-02-01), Kufe
patent: 6579854 (2003-06-01), Mitchell et al.
patent: 6767533 (2004-07-01), Casellas
patent: 6824561 (2004-11-01), Soykan
patent: 7125866 (2006-10-01), Glick
patent: 7144880 (2006-12-01), Glick
patent: 2001/0016583 (2001-08-01), Glick et al
patent: 2002/0025946 (2002-02-01), Buchanan
patent: 2002/0048566 (2002-04-01), El-Deiry et al.
patent: 2003/0044776 (2003-03-01), Dykens et al.
patent: 2003/0119029 (2003-06-01), Glick
patent: 2004/0009972 (2004-01-01), Ding
patent: 2004/0087489 (2004-05-01), Ruiz
patent: 2004/0176358 (2004-09-01), Glick
patent: 2005/0113460 (2005-05-01), Glick
patent: 2005/0261176 (2005-11-01), Glick
patent: 2005/0272723 (2005-12-01), Glick
patent: 2006/0025388 (2006-02-01), Glick
patent: 2006/0052369 (2006-03-01), Glick
patent: 1810423 (1969-10-01), None
patent: 0 227 539 (1986-12-01), None
patent: 0 349 949 (1990-01-01), None
patent: 0227539 (1990-05-01), None
patent: 1398033 (2004-03-01), None
patent: 2096044 (1997-11-01), None
patent: WO90/05305 (1990-05-01), None
patent: WO90/13332 (1990-11-01), None
patent: WO91/12779 (1991-09-01), None
patent: 92/01683 (1992-02-01), None
patent: 94/08234 (1994-04-01), None
patent: 98/57161 (1998-12-01), None
patent: WO99/29347 (1999-06-01), None
patent: WO99/58117 (1999-11-01), None
patent: WO 00/19200 (2000-04-01), None
patent: WO 0060106 (2000-11-01), None
patent: 02/67988 (2002-09-01), None
patent: 03/015703 (2003-02-01), None
patent: WO 03015703 (2003-02-01), None
patent: 05/004988 (2005-01-01), None
Tanimoto et al. Benzodiazepine Receptor agonists . . . , Japan J. Pharmacol. Vo. 79, pp. 177-183, 1999.
Kim et al., Synthesis of 3-substituted . . . , J. Braz. Chem. Soc. vol. 9, pp. 375-379, pp. 1998.
Zamzami et al., Mitochondrial control of nuclear Apoptosis(abstract only), J. Exp Med. Apr. 1, 1996, vol. 183(4), pp. 1293-1295.
Miccoli et al., Potentiation of Lonidamine and Diazepam . . . , Journal of the National Cancer Institute, vol. 90, No. 18, pp. 1400-1406. Sep. 1998.
Paola Costantini et al. “Mitochondrion as a Novel Target of Anticancer Chemotherapy”, JNCI Journal of the National Cancer Institute 2000 92(13):1042-1053; doi:10. 1093/jnci/92.13. 1042.
Ramdas et al., Benzodiazepine Compounds as Inhibitors of the Src Protein Tyrosine Kinase: Screening of a Combinatorial Library of 1,4-Benzodiazepines, Archives of Biochemistry and Biophysics vol. 368, No. 2, Aug. 15, pp. 394-400, 1999.
Giuseppe et al., Association of Tyrosine Protein Kinase Activity With Mitochondria in Human Fibroblasts, Journal of Cellular Biochemistry 32: 113-123 (1986).
Arnaud Beurdeley-Thomas et al., The peripheral benzodiazepine receptors: a review Journal of Neuro-Oncology 46: 45-56, 2000.
Parks, Daniel J. Bioorg Med Chem. Ltrs,. 15,(2005), 765-770.
Raboisson, P. Bioorg Med Chem. Ltrs., 15,(2005), 1857-1861.
Hulme, C. J. Org. Chem., 63,(1998), 8021-8023.
Kamal, A. Synlett, 14,(2004), 2533-35.
Grasberger, Bruce L., J. Med. Chem., 48, (2005), 909-912.
Snyder, Jane R., Chemistry & Biol., 12, (2005), 477-484.
Williams, Darren, Chemistry & Biol., 11, (2004), 1251-1259.
Beurdeley-Thomas et al., Journal of Neuro-Oncology 46 (2000) 45-56.
Churcher et al., Bioorganic & Medicinal Chemistry Letters 13 (2003) 179-183.
Darrow et al., Bioorganic & Medicinal Chemistry Letters 8 (1998) 3127-3132.
Herranz, Medicinal Research Reviews 23 (2003) 559-603.
Ramdas et al., Archieves of Biochemistry and Biophysics 368 (1999) 394-400.
Ursini et al., J. Med. Chem. 43 (2000) 3596-3613.
Walser et al., J. Org. Chem. 38:3502-3507 (1973).
Kim et al., J. Braz. Chem. Soc. 9:375-379 (1998).
Schlumpf, M., et al., “Delayed Developmental Immunotoxicity of Prenatal Benzodiazepines,” Toxic. In Vitro—3(5):1061-1065(1994).
Köhler and Milstein, Nature, 256:495-497 [1975].
Kozbor et al., Immunol. Today, 4:72 [1983].
Huse et al., Science, 246:1275-1281 [1989].
Adachi, M., et al., “Aberrant Transcription Caused by the Insertion of an Early Transposable Element in an Intron of the Fas Antigen Gene ofIprMice,” PNAS. USA- 90:1756-1760 (1993).
Adelman, N.E., et al., Treatment of (NZB X NZW)F1 Disease with Anti-I-A Monoclonal Antibodies; J. Exp. Med.-158:1350-1355 (1983).
Baader, S.L., et al., “Uptake and Cytotoxicity of Ascorbic Acid and Dehydroascorbic Acid in Neuroblastoma (SK-N•SH) and Neuroedodermal (SK-N-LO) Cells,” Anticancer Research-14:221•228 (1994).
Beale, P.J., et al., “BCL-2 Family Protein Expression and Platinum Drug Resistance in Ovarian Carcinoma,” British Journal of Cancer- 82 (2) :436-440 (2000).
Cole et al., in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96 [1985].
Boojamra, C.G., et al., “Solid-Phase Synthesis of 1,4•Benzodiazepine-2,5-Diones. Library Preparation and Demonstration of Synthesis Generality,” J. Org . Chem.-62:1240-1256 (1997).
Bunin, BA., et al., “A General and Expedient Method for the Solid-Phase Synthesis of 1,4-Benzodlazepine Derivatives,” J. Am. Chem. Soc. -114:10997-10998 (1992).
Bunin, B.A., et al., “The Combinatorial Synthesis and Chemical and Biological Evaluation of a 1,4-Benzodiazepine Libra ,” PNAS USA-91:4708-4712 (1994).
Chumakov, A.M., et al., “Analysis of p53 Transactivation Through High-Affinity Binding Sites,” Oncogene-8:3005•3011 ( 1993).
Cohen, P.L., et al., “Lpr and gld: Single Gene Models of Systemic Autoimmunity and Lymphoproliferative Disease,” Annu. Rev. Immunol.—9:243-269 (1991).
Crabtree, R.H., “A New Type of Hydrogen Bond,” Science 282:2000-2001 1998.
Desoize, B., “Anticancer Drug Resistance and Inhibition of Apoptosis,” Anicancer Research -14:2291-2294 1994.
Doble, A., et al., “Labelling of Peripheral-Type Benzodiazepine Binding Sites in Human Brain with [3H]11195: Anatomical and Subcellular Distribution,” Brain Research Bulletin,18:49-61 1987.
Donadio, J.V., et al., Immunosuppressive Drug Therapy inLupus nephritis; American Journal of Kidney Diseases—21(3):239-250 1993.
Ermak, T.H., et al., “Treatment ofMurine lupuswith Monoclonal Antibody to L3T4,” Laboratory Investigation—61(4):447-456 1989.
Gallant, J.E., et al.,“Incidence and Natural Histor
Glick Gary D.
Opipari Anthony W.
Casimir Jones S.C.
Ebrahim Nabila G
Hartley Michael G
The Regents of the University of Michigan
LandOfFree
Compositions and methods relating to novel compounds and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods relating to novel compounds and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods relating to novel compounds and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4081744